Patrick Campbell

An analysis of data from patients with diabetes in VA nursing homes suggests 17% were being overtreated for diabetes and 23% were being potentially overtreated.

Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.

Released on March 21, the practice advisory from the American Academy of Neurology advocates for a management approach focused on optimization of medical therapies and exercise over stenting for reducing risk of recurrent events and death in patients with symptomatic intracranial atherosclerotic arterial stenosis

An analysis of survey responses from type 1 diabetes caregivers indicates 10.3% of respondents reported job loss, 26.8% reported experiencing financial difficulty, and 71.9% reporting increased stress levels during the pandemic.

Data from a within-trial cost-effectiveness evaluation of data from the Salt Substitute and Stroke Study suggest use of the 75% sodium chloride 25% potassium chloride salt substitute had a 95% probability of being cost-saving and a greater than 99.9% probability of being cost-effective.

Data from the COSMOS trial demonstrate use of a cocoa flavanol supplement in older adults could cut the risk of cardiovascular death by more than 25%.

A systematic review and meta-analysis details the apparent lack of significant difference for glycemic control observed with subcutaneous insulin infusions versus multiple daily injections in patients with type 1 diabetes using real-time continuous glucose monitoring.

Announced on March 16, the decision to stop the phase 3 EMPA-KIDNEY trial is based on the recommendation of the trial's Independent Data Monitoring Committee and Eli Lilly and Company expect to present full results at an upcoming medical conference.

After previous studies found an increase in the diagnosis of central precocious puberty, investigators launched a new study to assess whether decreases in physical activity might be linked to the increased diagnosis rate.

Funded by the ADA and ADCES, the 2022 National Standards for Diabetes Self-Management Education and Support are aimed at and were released in Diabetes Spectrum on March 9.

With the FDA approval announced by Cordis on March 10, the company is hopeful the S.M.A.R.T. RADIANZ Vascular Stent System can help optimize radial access and improve patient outcomes.

Using multiple composite scores to assess dietary quality, investigators use data from 9 NHANES cycles to provide an overview of the declining diet quality among older adults in the US from 2001-2018.

On March 8, the American College of Rheumatology and the Vasculitis Foundation released new guidance for diagnosis and management of Kawasaki disease, which serves as the final companion piece to a trio of other ACR/VF vasculitis guidelines released in July 2021.

The ESTIMABL2 trial indicates a follow-up strategy not involving use of radioiodine was noninferior to ablation strategies with radioiodine for the occurrence of functional, structural, and biologic events up to 3 years after thyroidectomy.

A retrospective cohort study suggests use of GLP-1 RAs was associated with a 21% reduction in risk of all-cause mortality in patients with type 2 diabetes and advanced-stage chronic kidney disease compared with DPP-4 inhibitors.

A randomized trial comparing the effects of immediate testing and disclosure versus delayed testing, results suggest disclosing results of APOL1 testing led to reductions in blood pressure and meaningful lifestyle changes among patients with hypertension.

New research from the US CDC's COVID-19 Response Team details the increased risks of severe COVID-19 infection associated with congenital heart defects.

An analysis of data from more than 100k pregnant women suggests a history of spontaneous abortion was associated with an 18% increase in risk of subsequent gestational diabetes, with a history of multiple spontaneous abortions associated with an even greater risk.

Data from the DISCHARGE trial provides evidence demonstrating computed tomography could be a safe alternative to catheterization in patients with stable chest pain and suspected CAD.

A cross-sectional study of more than 70k women suggests those with long or irregular menstrual cycles were at a 22% greater risk of NAFLD.

Data from the VITAL-AF trial indicate universal screening with single-lead ECGs among patients 65 years and older in primary care settings did not significantly increase in new atrial fibrillation diagnoses, but was more effective in patients aged 85 years or older.

Results of the VISION Cardiac Surgery study indicate measurements of hs-TnI the first day after surgery could provide insight into the risk of mortality in the first 30 days after cardiac surgery.

Multiple organizations, including the American Diabetes Association and the Endocrine Society, have released statements backing President Biden's call for insulin co-pay caps during his State of the Union Address on March 1.

Announced on March 1, the Breakthrough Device Designation from the FDA allows for use of Dexcom CGM technology in in-hospital settings and at other healthcare facilities.

An analysis comparing those who switched against those who did not, results of the study suggest switching levothyroxine generics did not result in a negative impact on TSH levels in adult patients.

A review of data from the prospective SmartCare-CAD trial details the primary drivers of nonparticipation in telerehabilitation programs among patients with cardiovascular conditions.

A retrospective review with nearly a year of follow-up indicates nearly 40% of newly diagnosed diabetes at COVID-19 admission regressed to prediabetes or normoglycemia at follow-up, suggesting stress hyperglycemia induced by COVID-19-related acute stress could be driving rates of diagnosis.

The CRL for bardoxolone methyl for treatment of CKD caused by Alport syndrome comes less than 3 months after an FDA advisory committee voted unanimously against approval of Reata Pharmaceutical's once-daily, orally administered activator of Nrf2.

A meta-analysis of studies assessing presence of pathological eating behaviors and risk of diabetic retinopathy was associated with a more than 3-fold increase in risk of retinopathy.

Announced by Reata Pharmaceuticals on February 25, the Complete Response Letter from the FDA for bardoxolone methyl comes a little over 2 months after an FDA advisory committee voted unanimously against approval of the once-daily, orally administered activator of Nrf2.